Đang chuẩn bị liên kết để tải về tài liệu:
PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): A pragmatic phase III randomized controlled trial

Positron emission tomography targeting the prostate specific membrane antigen (PSMA PET/CT) has demonstrated unparalleled performance as a staging examination for prostate cancer resulting in substantial changes in management. However, the impact of altered management on patient outcomes is largely unknown. |